For example, in a cohort of 127 patients (64 tumor-bearing subjects), Goodison et al. demonstrated that a panel based on two biomarkers (VEGF and apolipoprotein E [APOE]) had 81% sensitivity and 97% specificity for detecting BCa. This evidence concerns the gene APOE and neoplasm.